Literature DB >> 20851820

Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study.

L Valenti1, S Moscatiello, E Vanni, A L Fracanzani, E Bugianesi, S Fargion, G Marchesini.   

Abstract

BACKGROUND/AIM: To test the short-term clinical usefulness of venesection associated with lifestyle counselling as against counselling alone on insulin resistance and liver enzymes in subjects with non-alcoholic fatty liver disease (NAFLD), using a propensity score approach.
METHODS: We carried out a 6- to 8-month observational analysis of 198 NAFLD patients in three Italian referral centres (79 venesection and 119 counselling alone). Insulin resistance was measured by the homeostasis model assessment (HOMA) method. Logistic regression was used to identify factors associated with normal HOMA and normal alanine aminotransferase (ALT) at the end of observation. The results were adjusted for the propensity score to be enrolled in the venesection programme, based on clinical and laboratory data, including common HFE polymorphisms and liver biopsy (available in 161 cases).
RESULTS: After adjustment for propensity and changes in BMI, venesection was significantly associated with normal HOMA [all cases: odds ratio (OR) 3.00; 95% confidence interval (CI) 1.51-5.97; cases with histology: OR 2.29; 95% CI 1.08-4.87] and ALT within normal limits (all cases: OR 2.56; 95% CI 1.29-5.10; cases with histology: OR 2.81; 95% CI 1.20-5.24). The results were confirmed in an analysis of 57 pairs matched for propensity, where venesection similarly increased the probability of normal HOMA (OR 3.27; 95% CI 1.16-7.84) and normal ALT (OR 5.60; 95% CI 2.09-15.00). Similar data were obtained in the subset of cases with normal basal ferritin (<350 ng/ml).
CONCLUSION: Iron depletion by venesection favours the normalization of insulin resistance and raised liver enzymes in non-haemochromatosis patients with NAFLD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851820     DOI: 10.1093/qjmed/hcq170

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  18 in total

Review 1.  Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver.

Authors:  Elmar Aigner; Günter Weiss; Christian Datz
Journal:  World J Hepatol       Date:  2015-02-27

2.  A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Paola Dongiovanni; Serena Rovida; Raffaela Rametta; Erika Fatta; Edoardo Alessandro Pulixi; Marco Maggioni; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  Iron metabolism in Nonalcoholic Fatty Liver Disease.

Authors:  James E Nelson; Heather Klintworth; Kris V Kowdley
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 4.  Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease.

Authors:  Luca Valenti; Paola Dongiovanni; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

5.  Pharmacological agents for nonalcoholic steatohepatitis.

Authors:  Maeva Guillaume; Vlad Ratziu
Journal:  Hepatol Int       Date:  2013-11-19       Impact factor: 6.047

Review 6.  Lytic cell death in metabolic liver disease.

Authors:  Jérémie Gautheron; Gregory J Gores; Cecília M P Rodrigues
Journal:  J Hepatol       Date:  2020-04-13       Impact factor: 25.083

7.  Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload.

Authors:  Sandhya R Panch; Yu Ying Yau; Kamille West; Karen Diggs; Tamsen Sweigart; Susan F Leitman
Journal:  Transfusion       Date:  2014-09-11       Impact factor: 3.157

8.  ENO3 promoted the progression of NASH by negatively regulating ferroptosis via elevation of GPX4 expression and lipid accumulation.

Authors:  Di Lu; Qiaoyun Xia; Zhiyu Yang; Shanjun Gao; Suofeng Sun; Xiaoying Luo; Zhen Li; Xiulei Zhang; Shuangyin Han; Xiuling Li; Mingbo Cao
Journal:  Ann Transl Med       Date:  2021-04

9.  Body iron, serum ferritin, and nonalcoholic fatty liver disease.

Authors:  Jae-Jun Shim
Journal:  Korean J Hepatol       Date:  2012-03-22

10.  Obesity alters adipose tissue macrophage iron content and tissue iron distribution.

Authors:  Jeb S Orr; Arion Kennedy; Emily K Anderson-Baucum; Corey D Webb; Steve C Fordahl; Keith M Erikson; Yaofang Zhang; Anders Etzerodt; Søren K Moestrup; Alyssa H Hasty
Journal:  Diabetes       Date:  2013-10-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.